Selander KS - Search Results

1

Toll-like receptor 9 mediates invasion and predicts prognosis in squamous cell carcinoma of the mobile tongue.

Kauppila JH, Korvala J, Siirilä K, Manni M, Mäkinen LK, Hagström J, Atula T, Haglund C, Selander KS, Saarnio J, Karttunen TJ, Lehenkari PP, Salo T. Kauppila JH, et al. Among authors: selander ks. J Oral Pathol Med. 2015 Sep;44(8):571-7. doi: 10.1111/jop.12272. Epub 2014 Oct 23. J Oral Pathol Med. 2015. PMID: 25338738

2

The effects of bisphosphonates on the resorption cycle of isolated osteoclasts.

Selander K, Lehenkari P, Väänänen HK. Selander K, et al. Calcif Tissue Int. 1994 Nov;55(5):368-75. doi: 10.1007/BF00299317. Calcif Tissue Int. 1994. PMID: 7532540

3

Estrogen receptor alpha genotype confers interindividual variability of response to estrogen and testosterone in mesenchymal-stem-cell-derived osteoblasts.

Leskelä HV, Olkku A, Lehtonen S, Mahonen A, Koivunen J, Turpeinen M, Uusitalo J, Pelkonen O, Kangas L, Selander K, Lehenkari P. Leskelä HV, et al. Bone. 2006 Nov;39(5):1026-1034. doi: 10.1016/j.bone.2006.05.003. Epub 2006 Jun 16. Bone. 2006. PMID: 16782420

4

Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity.

Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS. Merrell MA, et al. Among authors: selander ks. Mol Cancer Res. 2006 Jul;4(7):437-47. doi: 10.1158/1541-7786.MCR-06-0007. Mol Cancer Res. 2006. PMID: 16849519

5

Differential effects of Ca(2+) on bisphosphonate-induced growth inhibition in breast cancer and mesothelioma cells.

Merrell MA, Wakchoure S, Ilvesaro JM, Zinn K, Gehrs B, Lehenkari PP, Harris KW, Selander KS. Merrell MA, et al. Among authors: selander ks. Eur J Pharmacol. 2007 Mar 15;559(1):21-31. doi: 10.1016/j.ejphar.2006.11.064. Epub 2006 Dec 9. Eur J Pharmacol. 2007. PMID: 17214981

6

Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro.

Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW, Selander KS. Ilvesaro JM, et al. Among authors: selander ks. Prostate. 2007 May 15;67(7):774-81. doi: 10.1002/pros.20562. Prostate. 2007. PMID: 17373717

7

Inhibition of cyclooxygenase-2 down-regulates osteoclast and osteoblast differentiation and favours adipocyte formation in vitro.

Kellinsalmi M, Parikka V, Risteli J, Hentunen T, Leskelä HV, Lehtonen S, Selander K, Väänänen K, Lehenkari P. Kellinsalmi M, et al. Eur J Pharmacol. 2007 Oct 31;572(2-3):102-10. doi: 10.1016/j.ejphar.2007.06.030. Epub 2007 Jun 29. Eur J Pharmacol. 2007. PMID: 17632097

8

Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.

Merrell MA, Wakchoure S, Lehenkari PP, Harris KW, Selander KS. Merrell MA, et al. Among authors: selander ks. Eur J Pharmacol. 2007 Sep 10;570(1-3):27-37. doi: 10.1016/j.ejphar.2007.05.075. Epub 2007 Jun 16. Eur J Pharmacol. 2007. PMID: 17640631

9

Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.

Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, Rahko E, Jukkola-Vuorinen A, Vuopala KS, Harris KW, Selander KS. Ilvesaro JM, et al. Among authors: selander ks. Mol Cancer Res. 2008 Oct;6(10):1534-43. doi: 10.1158/1541-7786.MCR-07-2005. Mol Cancer Res. 2008. PMID: 18922969

10

Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.

Väisänen MR, Väisänen T, Jukkola-Vuorinen A, Vuopala KS, Desmond R, Selander KS, Vaarala MH. Väisänen MR, et al. Among authors: selander ks. Prostate. 2010 Jun 1;70(8):817-24. doi: 10.1002/pros.21115. Prostate. 2010. PMID: 20054821

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters